E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8346196.
- Also identified by PMC identifier 47045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous studies have shown that the carboxyl-terminal region of E2F-1 (residues 368-437) can support transcriptional activation when linked to the DNA-binding domain of the yeast transcription factor GAL4. This region also contains an 18-residue retinoblastoma (RB)-binding sequence, raising the possibility that RB binding might inhibit the ability of E2F-1 to form protein-protein contacts required for activation. Here we report a further analysis of the E2F-1 activation domain. In addition, we show that overexpression of RB, but not the RB mutant, RBd22, can inhibit GAL4/E2F-1 activity in vivo. Moreover, expression of the simian virus 40 large tumor antigen (T antigen), but not the RB-binding defective T antigen point mutant, K1, can overcome this repression. Three different GAL4/E2F-1 mutants that activate transcription, but fail to bind to RB, are not significantly affected by overexpression of RB. These findings support a model wherein RB suppresses E2F-1-mediated transcriptional activation through direct physical association.
Medical subject headings
- Carrier Proteins
- Cell Cycle Proteins
- DNA-Binding Proteins
- Gene Expression Regulation
- Retinoblastoma Protein
- Transcription Factors
- Transcription, Genetic
- Transcriptional Activation